Heart Disease News and Research

Latest Heart Disease News and Research

NIH awards grant to conduct genetic drug research on cancer and heart disease

A Virginia Tech chemist has been awarded a $2.3 million grant from the National Institutes of Health (NIH) to conduct research that will aid in the development of new heart disease and cancer medicines that have fewer side effects.

15 Oct 2009

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.

15 Oct 2009

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Pregnant women are advised to take vitamin supplements containing folic acid as part of their routine pre-natal care. Now, a new study warns that taking medications that reduce or block the actions of folic acid during the first trimester of pregnancy increase the risk that the growing baby will develop abnormalities.

14 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

MAQUET Cardiovascular officially opens its new headquarters in Wayne

MAQUET Cardiovascular LLC, a leading, global provider of cardiovascular technologies, today celebrated and formally opened its new United States headquarters in Wayne, New Jersey. The dedication ceremony was attended by local and state dignitaries, the MAQUET leadership team, and local employees from the company's cardiovascular, critical care and surgical workplace divisions.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Preliminary results of its tender offer announced by Cardiome Pharma

Cardiome Pharma Corp. announced the preliminary results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.

14 Oct 2009

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Today, Lung Cancer Alliance (LCA) hailed the support of Senators Chuck Schumer (D-NY) and Kirsten Gillibrand (D-NY) who have signed on as co-sponsors of a bill to establish the first ever multi-agency, comprehensive program targeted at lung cancer.

14 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

State-level education policy essential to reverse childhood obesity

The new issue of The State Education Standard, the journal of the National Association of State Boards of Education (NASBE), examines how education policymakers can best address childhood obesity in school settings.

14 Oct 2009

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").

14 Oct 2009

ATS CryoMaze Probe receives CE Mark

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the receipt of CE Mark for the ATS CryoMaze® 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.

14 Oct 2009

International Stem Cell launches human cell culture products into commercial research markets

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs.

14 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

National study shows people who work after retiring experience fewer major diseases

Retirees who transition from full-time work into a temporary or part-time job experience fewer major diseases and are able to function better day-to-day than people who stop working altogether, according to a national study. And the findings were significant even after controlling for people's physical and mental health before retirement.

14 Oct 2009

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Galapagos NV announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.

14 Oct 2009

American Recovery and Reinvestment Act funds to support research in numerous health areas

As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas.

14 Oct 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

Heart Disease News and Research

Latest Heart Disease News and Research

NIH awards grant to conduct genetic drug research on cancer and heart disease

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

MAQUET Cardiovascular officially opens its new headquarters in Wayne

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Women with breast cancer can improve their mental health through Transcendental Meditation technique

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Preliminary results of its tender offer announced by Cardiome Pharma

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

State-level education policy essential to reverse childhood obesity

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

ATS CryoMaze Probe receives CE Mark

International Stem Cell launches human cell culture products into commercial research markets

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

National study shows people who work after retiring experience fewer major diseases

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

American Recovery and Reinvestment Act funds to support research in numerous health areas

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Heart Disease News and Research

Latest Heart Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in